

PCT

**WORLD INTELLECTUAL PROPERTY ORGANIZATION**  
**International Bureau**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6-: <b>A61K 31/00</b>		A2	(11) International Publication Number: <b>WO 98/06387</b> (43) International Publication Date: <b>19 February 1998 (19.02.98)</b>
<p>(21) International Application Number: <b>PCT/EP97/04376</b></p> <p>(22) International Filing Date: <b>12 August 1997 (12.08.97)</b></p> <p>(30) Priority Data: 9617001.4                    13 August 1996 (13.08.96)                    GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): <b>TILLOTT'S PHARMA AG [CH/CH]; Hauptstrasse 27, CH-4417 Ziefen (CH).</b></p> <p>(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): <b>BUSER, Thomas [CH/CH]; Hauptstrasse 27, CH-4417 Ziefen (CH).</b></p> <p>(74) Agent: <b>McMUNN, Watson, P.; W.H. Beck, Greener &amp; Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).</b></p>		<p>(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p><b>(54) Title:</b> <b>ORAL COMPOSITION</b></p> <p><b>(57) Abstract</b></p> <p>A topical spreadable composition comprising 5-aminosalicylic acid (5-ASA) as active and monoolein is provided for treatment ulcers, inflammation and lesions of the oral cavity. The composition is spread over and adheres to the lesion, and is preferably prepared in a water free state. Examples of indications that can be treated are oral Crohn's Disease, aphous ulcers, orofacial granulomatosis, oral ulcers associated with Behet's disease and oral <i>lichen planus</i>.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

Oral Composition

This invention relates to a 5-aminosalicylate acid (5-ASA) composition for the treatment or prophylaxis of 5 oral ulcerations, inflammation and lesions of the oral cavity, and in particular the use the glyceryl monooleate in the preparation of such compositions.

Oral ulceration (or mouth ulcers) can be very 10 painful and the resulting lesions can be mild or severe. There are various preparations for the treatment of oral ulcerations. For example carbenoxolone sodium can be helpful in promoting healing of mild oral lesions, lozenges and oral pastes containing corticosteroids are 15 used for treating aphous non-specific ulcers, salicylates can be used in mild inflammatory and painful oral lesions, and benzydamine hydrochloride has a topical anti-inflammatory and analgesic effect and is used as a mouthwash or spray for oral ulcerations. A difficulty of 20 treating oral ulcerations with preparations such as sprays, lozenges and mouthwash is that the active agent of the preparation is only transiently in contact with the ulcer. Even with gelatin based pastes, which have a protective effect for non-infected ulcers, it is 25 difficult to keep them on the lesion for a prolonged period.

An example of a mucoprotectant is orabase<sup>TM</sup> which 30 contains carmellose sodium, pectin and gelatin. This composition, however, has an uncomfortable gritty mouthfeel.

5-aminosalicylic acid (5-ASA) is a known compound and is currently used in the treatment of inflammatory bowel disease such as Crohn's disease and ulcerative colitis. For these indications, 5-ASA is administered rectally as an enema, or orally as a controlled release capsule. EP-A-0 352 826 relates to the use of 5-ASA for dermatological disorders associated with therapy-resistant loss of epithelium, such as pyoderma gangrenosum, leg ulcers, mouth ulcers, decubitus, bullous dermatoses and burns. In addition, 5-ASA is water sensitive and therefore it is desirable to formulate it in a substantially water free composition.

15 Topical 5-ASA in a guaze poultice has also been reported as treating oral and genital lesions resulting from Behcet's disease (British J. Dermatol., 1989, 120:471-72).

20 It is an object of the present invention to provide an effective treatment for oral ulceration, inflammation and lesions of the oral cavity, in particular of the tongue, gingivae, lips, palate and buccal mucosa.

25 We have now surprisingly found an effective medicament for treating oral ulcerations inflammation, and lesions of the oral cavity which comprises 5-ASA as active agent or a physiologically acceptable derivative thereof, and glyceryl monooleate. The glyceryl  
30 monooleate is conveniently spread in a thin film over the ulcer and forms an adhesive bond with the mucous of the

ulcer, which in turn maintains the 5-ASA in contact with the ulcer for a prolonged period. Furthermore, we have found that the glyceryl monooleate can be used in a substantially water free state, which helps to stabilise 5 the 5-ASA and prolong the shelf life of the composition.

Preferably, monoolein (containing glyceryl monooleate) is used in the composition of the invention.

10 By monoolein we mean a product which consists predominantly of glyceryl monooleate, although various other glycerides of oleic acid and other fatty acids could be present. Hereinafter references to glyceryl monooleate should be construed also as a reference to 15 monoolein (CAS Registry No. 25496-72-4) and visa versa.

Preferably glyceryl monooleate (and monoolein) is formulated in a substantially water-free state. This enhances the shelf life of the composition.

20 Monoolein is a mixture of the glycerides of oleic acid and other fatty acids, consisting mainly of the glyceryl monooleate. A commercial form of monoolein is sold by Eastman Chemicals (e.g. at Hemel Hempstead, UK or 25 Denver, USA) under the trade name Myverol™. The manufacturers recommended uses of Myverol™ are: for sustained release formulations, for topical permeation enhancement, for solubilisation of a water soluble drug into an oil matrix, and for sustained release 30 microspheres. Monoolein is normally formulated in its fully hydrated cubic phase (which contains up to about

40% water) to produce its advantageous sustained release properties (J.Phys.Chem.1989, 93, 7304-7314 and EP-A-0 314 689).

5       A composition comprising monoolein and an active such as metronidazole (an antibacterial) is described in EP-A-0 671 175 and equivalent US-A-5 261 164 as a sustained release product for treating periodontal disease. The composition is injected into the  
10 periodontal pocket, preferably by a syringe. Such a product is sold under the trade name elyzol™ which is issued with a disposable applicator for the treatment of chronic periodontal disease. Similar periodontal type applications of monoolein are disclosed in Pharmaceutical  
15 Technology Europe Feb 1995, p14-16, and J.Clin. Periodontal 1992; 19:687-692.

Accordingly in a first aspect of the present invention there is provided a spreadable mucoadhesive  
20 topical pharmaceutical composition comprising 5-ASA or a physiologically acceptable derivative thereof, and glyceryl monooleate.

By physiologically acceptable derivative, we mean a  
25 derivative which is metabolised *in vivo*, such as by the enzymes in the oral cavity, to the same active metabolite as 5-ASA, and in particular includes physiologically acceptable salts and esters of 5-ASA.

30       An example of a derivative of 5-ASA is an N-acetyl derivative and its salts. Some esters have similar

activity, e.g. alkyl esters, especially lower alkyl esters such as methyl, ethyl, propyl or isopropyl; alkenyl esters; cycloalkyl esters; aryl esters; alicyclic esters; and aralkyl esters.

5

Examples of physiologically acceptable salts of 5-ASA and its derivatives include salts derived from an appropriate base, such as an alkali metal (for example sodium or potassium), an alkaline earth metal (for example magnesium), ammonium or  $\text{NX}_4^+$ , wherein X is a  $\text{C}_{1-4}$  alkyl group.

Most oral ulcerations or lesions should respond to treatment with a composition of the present invention particularly including the following: oral aphthous ulcers, oral mucositis (including mucositis neuroticans agranulocytica), oral Crohn's disease, ulcers in patients with ulcerative colitis, orofacial granulomatosis, denture stromatitis, oral ulcers associated with Behet's Disease, oral lichen planus, pemphigus of the mouth, herpetic ulcers and traumatic lesions. By lesion we mean to include papule, nodule, weal, vesicle, bulla, plaque, scale, excoriation, scar, and lichenification.

Oral mucositis is an inflammation of the oral mucous surface and, for example, can result from chemotherapy.

Symptoms of oral Crohn's disease can include thickening of the mucous membranes of the mouth and lip.

30

Symptoms of orofacial granulomatosis can include furrowing of the tongue, thickening of the lower lip and buccal mucosa, and recurrent aphthous ulcers.

5       The composition of the invention is ideally suited for treating oral ulceration, inflammation and lesions of the tongue, palate, lips, gingivae and most preferably the buccal mucosa.

10      Optional components which can also be used in the composition include anaesthetic agents, flavourings, surfactants, penetration enhancers, antioxidants, polymers, opacifiers, viscosity modifying agents including hydrocarbon waxes or oils such as glycerol. In  
15     a preferred embodiment white soft paraffin wax is used to improve the rheological behaviour of glyceryl monooleate (i.e. improve its spreadability). Surprisingly, the white soft paraffin also helps prevent sedimentation of solids in the formulation as compared to other oils such  
20     as paraffin, glycerol, and arachis oil.

Other preferred optional components are titanium dioxide as an opacifier, lidocaine hydrochloride as an anaesthetic, benzyl alcohol as a penetration enhancer and  
25     ascorbyl palmitate as an antioxidant. Ascorbyl palmitate is a particularly good antioxidant in a substantially water-free composition of the invention.

The amount of each component in a formulation can  
30     vary. Thus 5-ASA could be used at up to 20% w/w, more preferably 1% to 10% w/w, preferably 3% to 7% w/w and

most preferably about 5% w/w. Glyceryl monooleate (or monoolein) can be present at 10% to 99% w/w, preferably 20% to 80% w/w, more preferably 40% to 60% w/w and most preferably about 50% w/w. Where the total weight is less than 100% w/w, the formulation would be made up with other optional components. For example, a hydrocarbon wax, such as white soft paraffin, is desirably used at 10% to 50% w/w, preferably 25% to 45% w/w, most preferably about 35% w/w. An anaesthetic agent, such as lidocaine, is desirably used at 1% to 5% w/w, preferably about 3% w/w. An antioxidant such as ascorbyl palmitate is desirably used at 0.1 to 1% w/w, preferably 0.3% to 0.7% w/w, most preferably about 0.5% w/w. Typically the composition can be administered in a 5g or 10g tube.

15

A particularly preferred embodiment of the invention includes 5-ASA or a physiologically acceptable salt thereof, at 3% to 7% w/w, glyceryl monooleate at 40% to 60% w/w, hydrocarbon wax, preferably white soft paraffin, at 25% to 45% w/w, anaesthetic, preferably lidocaine hydrochloride at 1% to 5% w/w, ascorbyl palmitate at 0.1% to 1% w/w, preferably 0.3 to 0.7% and optional other components.

25

The composition of the invention is typically supplied from a tube or pump dispenser and spread topically using the finger tip in a smearing action over, for example, the oral ulcer. In this way a thin mucoadhesive film is formed which is comfortable and convenient for the patient. In addition, the glyceryl monooleate film protects the ulcer from further infection

and, because it is substantially insoluble in saliva, it prevents the 5-ASA from being washed off the ulcer. As such, with intermittent applications a therapeutically effective amount of 5-ASA can be maintained in continuous contact with the ulcerous lesion thereby accelerating healing of the lesion. Typically a 5g tube of the composition will contain about one hundred doses.

Further aspects of the invention are as follows:

10

1. The use of glyceryl monooleate as a mucoadhesive in the preparation of a spreadable 5-ASA medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity.

15

2. Use of 5-ASA or a physiologically acceptable derivative thereof as an active in a glyceryl monooleate containing topical medicament for the treatment of oral ulcerations, inflammation, or lesions of the oral cavity.

20

3. The use of 5-ASA or a physiologically acceptable derivative thereof and glyceryl monooleate in the preparation of a spreadable medicament for the topical treatment of oral ulcerations, inflammation, or lesions of the oral cavity.

25

4. A method of treating oral ulcerations, inflammation, or lesions of the oral cavity comprising spreading topically over the ulcer lesion, or inflamed mucosa, a pharmaceutical formulation comprising an

30

effective amount of 5-ASA or a physiologically acceptable derivative thereof, and glyceryl monooleate.

5 5. Since we have also discovered that 5-ASA can particularly treat oral aphthous ulcers, oral mucositis, oral Crohn's disease and orofacial granulomatosis, a yet further aspect of the invention relates to the use of 5-ASA (in any composition) for the treatment of these oral disorders.  
10

The invention will now be described by way of example with reference to the following compositions.

15

Example 1

Active Constituent % w/w

5-Aminosalicylic acid 5.0

Other Constituents

20 Myverol™ 18-99 53.5

(Monoglyceride)

White Soft Paraffin 35.0

Titanium Dioxide 5.0

Benzyl Alcohol 1.0

25 Ascorbyl Palmitate 0.5

Total: 100.0

Example 2

Example 1 was repeated, but without the addition of benzyl alcohol, and compensated for by increasing the  
5 weight of white soft paraffin.

Example 3

Example 1 was substantially repeated but lidocaine  
10 hydrochloride was additionally added as a local anaesthetic and benzyl alcohol taken out. The % w/w Myverol™ was decreased by a few units.

Example 4

15 Oral mucositis following chemotherapy is a common problem. 15 patients suffering from oral mucositis were asked to apply a 5-ASA/myverol composition prepared in accordance with Example 1. All patients used  
20 chlorohexidine mouthwash and may have received benzydamine hydrochloride mouthwash and opioid analgesics. Each patient was asked to fill in a questionnaire at the end of a fifteen month study period. Of the 14 replies received, 2 patients were unable to  
25 recall details. Of the remaining 12 patients, 10 derived "overall" pain relief, 9 deriving relief on eating, 7 on drinking, and only 2 reported discomfort on application.

This study suggests that topical 5-ASA, particularly  
30 in a topical glyceryl monooleate composition, is of

benefit in the management of chemoradiotherapy induced mucositis.

Example 5

5

A 14 year old boy with Crohn's Disease was asked to apply the composition in accordance with Example 1` twice daily for six weeks. The oral Crohn's Disease produced a thickening of the mucous membranes in the mouth and lip  
10 and in this patient was associated with perianal disease. During the treatment there was also a clear improvement inside the mouth, but very little difference to the lips.

Example 6

15

A 12 year old boy with Melkerson-Rosenthal syndrome or orofacial granulomatosis had biopsies taken from his mouth which did not show granulomas diagnostic of Crohn's Disease. Otherwise the patient had symptoms identical to  
20 oral Crohn's Disease, but there was no evidence of a gut problem.

The patient's symptoms included thickening of the lower lip and buccal mucosa, furrowing of the tongue and  
25 recurrent apthous ulceration. After one month applying a composition in accordance with the examples, the patient was very pleased with his progress. Remarkably he developed only two ulcers during the treatment period.

30

CLAIMS

1. A spreadable mucoadhesive topical pharmaceutical composition comprising 5-ASA or a physiologically acceptable derivative thereof and glyceryl monooleate.
2. A composition as claimed in Claim 1 wherein glyceryl monooleate is formulated substantially water-free.
3. A composition as claimed in Claims 1 or 2 which further contains a hydrocarbon wax as a viscosity modifier.
4. A composition as claimed in any one of the preceding claims wherein the hydrocarbon wax is white soft paraffin.
5. A composition as claimed in anyone of the preceding claims comprising 3% to 7% w/w of 5-ASA or a physiologically acceptable derivative thereof, 40% to 60% w/w glyceryl monooleate, 25% to 45% w/w white soft paraffin, 1% to 5% w/w anaesthetic agent, and 0.1% to 1% w/w ascorbyl palmitate.
6. A composition as claimed in any one of the preceding claims wherein glyceryl monooleate is present as monoolein.
7. The use of glyceryl monooleate as a mucoadhesive in the preparation of a spreadable 5-ASA medicament for

the topical treatment of oral ulcerations,  
inflammation and lesions of the oral cavity.

8. Use of 5-ASA or a physiologically acceptable derivative thereof as an active in a glyceryl monooleate containing topical medicament for the treatment of oral ulcerations, inflammation and lesions of the oral cavity.  
5
- 10 9. The use of 5-ASA or a physiologically acceptable derivative thereof and glyceryl monooleate in the preparation of a spreadable medicament for the topical treatment of oral ulcerations, inflammation and lesions of the oral cavity.